


TRANSLATIONAL CANCER RESEARCH

ANNUAL REPORT
2024






Outline of the Report

1. Basic Information
2. Editors-in-Chief
3. Geographical Distributions of Editorial Board Members
4. Diverse Types of Articles Published in 2024
5. Users of Website in 2024
6. Website Pageviews of Website in 2024
7. Citations (results over past five years)
8. Top 10 Most Read Articles Published in 2024
9. Ongoing Special Series and Guest Editor (2024)
10. Reviewer of the Month (2024)
11. Interviews with Outstanding Authors (2024)
12. Interviews with Editorial Board Members (2024)
13. Interviews with Guest Editors (2024)
14. Introduction of the Publisher AME

1. Basic Information

- Open Access
- Peer Reviewed
- Launched in June 2012
- Indexed in **Web of Science [Science Citation Index Expanded (SCIE)]** and **Scopus** in 2015
- Indexed in **PubMed/PubMed Central**
- Published Bi-monthly (Jun. 2012 - Aug. 2019), monthly (Sep. 2019 -)
- **Impact Factor (2023): 1.5**
- Publishing the results of novel research investigations which bridge the laboratory and clinical settings with the overall goal of improving the clinical care of cancer patients.




2. Editors-in-Chief

Editor-in-Chief



Eric Y Chuang, ScD, EMBA
Graduate Institute of Biomedical,
Electronics and Bioinformatics;
National Taiwan University, Taipei

Co-Editor-in-Chief



Huan Giap, MD, PhD
Medical Director, Proton Beam Therapy, OSF
Healthcare Cancer Institute, University of
Illinois, Peoria, IL, USA.; Clinical Professor,
University of Illinois, School of Medicine
Peoria, IL, USA.

Message from Editors-in-Chief

On behalf of the TCR editorial team, we would like to express sincere appreciation for the continuing support and contributions from all editorial board members, guest editors, authors, reviewers and readers etc. Looking forward to work more closely with you in the new year 2025!




Eric Y Chuang, Sc.D
EIC of TCR
Professor, Graduate Institute of
Biomedical Electronics and
Bioinformatics
National Taiwan University,
Taipei, Taiwan



Huan Giap, MD, PhD
Co-EIC of TCR
Associate Professor, Dept of Radiation
Oncology, University of Miami Sylvester
Comprehensive Cancer Center
Adjunct Clinical Professor, Department of
Radiation Medicine and Applied Sciences,
University of California at San Diego


3. Geographical Distribution of Editorial Board Members



All together **51** worldwide experts being the editorial board members:

- 1 Editor-in-Chief
- 1 co-Editor-in-Chief
- 2 Associate Editors-in-Chief
- 47 Editorial board members

4. Diverse Types of Articles Published in 2024




In 2024, TCR has published **521** articles and the proportion of Original Article and Review Article takes up to **90%**.

5. Users of Website in 2024

Country	Active users	New users
United States	103,788	102,939
China	51,806	49,538
India	29,241	28,872
United Kingdom	22,211	22,027
Canada	12,959	12,753
Australia	11,626	11,473
Japan	11,589	11,235
South Korea	9,960	9,641
Germany	8,630	8,388
Italy	8,367	8,128


Active users by Country over time



From Jan 1st , 2024 to Dec 31st, 2024, TCR has a total of **422, 444** active users. The readership of TCR spans 218 countries and regions, with the largest user bases coming from the United States, China, and India.

(Note: Data were collected from Google Analytics on Jan. 6, 2025.)


6. Website Pageviews of Website in 2024



In 2024, the website pageviews of TCR reached **1,435,274**, an increase of **23%** over 2023. The month with the highest pageviews is July —**137,193**.

(Note: Data were collected from Google Analytics on Jan. 6, 2025.)

7. Citations (results over past five years)



The citation of TCR has been increasing steadily.

Since TCR was launched, its articles have been cited **18,561** times by articles indexed in Web of Science Core Collection, with an average of **1,325.79** citations per year.

The yearly citations of TCR has increased to **4,654** in 2024.

(Note: Data were collected from Web of Science™ on Jan 6, 2025).

8. Top 10 Most Read Articles Published in 2024

Title	All authors	Pageviews
Comprehensive profiling of cell subsets of gastric cancer and liver metastasis based on single cell RNA-sequencing analysis	Meng Pan, Peng Chen, Qi Zhang, Yuquan Yang, Weichao Hu, Guanglong Hu, Rongsheng Wang, Xiaopeng Chen	2349
A novel lactylation-related gene signature for effectively distinguishing and predicting the prognosis of ovarian cancer	Lei Yu, Chunxia Jing, Sulian Zhuang, Liwei Ji, Li Jiang	2323
The m5C/m6A/m7G-related non-apoptotic regulatory cell death genes for the prediction of the prognosis and immune infiltration status in hepatocellular carcinoma	Xiangyu Qu, Yigang Zhang, Haoling Li, Yi Tan	2152
The role of IQCB1 in liver cancer: a bioinformatics analysis	Dongmei Han, Bin Ling, Caihong Wu, Hao Jin	2144
Disulfidptosis-related gene SLC7A11 predicts prognosis and indicates tumor immune infiltration in lung adenocarcinoma	Jing Zhu, Hui Ge, Yinsong Chen, She Zhang, Junjie Wu, Weiping Nai, Lingfeng Min	2133

*Data source: <https://tcr.amegroups.org/article/mostRead?queryYear=2024>; collected on Jan 3, 2025.

8. Top 10 Most Read Articles Published in 2024

Title	All authors	Pageviews
Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation	Meng Wang, Zeyu Xu, Ziyang Wang, Xiaowan Xu, Yongning Sun	2089
Comprehensive analysis of the effects of the cuprotosis-associated gene SLC31A1 on patient prognosis and tumor microenvironment in human cancer	Guiqian Zhang, Ning Wang, Shixun Ma, Pengxian Tao, Hui Cai	2084
RBM39 is a potential prognostic biomarker with functional significance in hepatocellular carcinoma	Fangfang Cui, Wenling Wang, Chunbo Zhuang, Dezhi He, Pei Wang	2016
TCF4 as a potential prognostic biomarker and an anticancer target in gastric cancer	Hailong Wang, Arvind Sahu, Michael D. Chuong, Ruiping Li	2013
Prognostic biomarkers based on GUF1, EFTUD2 and GSPT1 targets affecting migration of gastric cancer cells	Haixiu Ma, Lina Suo, Jing Zhao, Ronghua Ma, Qi Wang, Jun Liu, Jinwan Qiao, Juan Wu, Juan An, Yan Liu, Yonghua Xing, Haiyan Wang, Zhanhai Su	1962

*Data source: <https://tcr.amegroups.org/article/mostRead?queryYear=2024>; collected on Jan 3, 2025.

9. Ongoing Special Series

Current Status of Robotic Surgery for Genitourinary Diseases in Japan

GUEST EDITOR



TAKUYA KOIE




Scan to learn the
series outline

10. Reviewer of the Month (2024)

In 2024, TCR reviewers continue to make outstanding contributions to the peer review process. Hereby, we would like to highlight some of our outstanding reviewers. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

January, 2024

Felipe Andrés Cordero da Luz



Dr. Felipe Andrés Cordero da Luz is a senior researcher in public health at the Cancer Prevention and Research Project Center of the Luta Pela Vida Group, a non-profit organization focused on the treatment of cancer patients, prevention, and cancer research. He graduated in biomedicine and received his Master's and Doctor of Science degrees from the Postgraduate Program in Applied Immunology and Parasitology at the Federal University of Uberlândia. He specializes in Applied Statistics and an MBA in Clinical Research. His main interests focus on breast cancer, ranging from basic to clinical research. He is currently the developer and one of the managers of two projects approved by the Ministry of Health, one focusing on the estradiol signaling pathway through the beta estrogen receptor and the other on the development of machine learning algorithms to support clinical decision-making regarding chemotherapy in breast cancer. You can find his [LinkedIn](#) or learn more about him [here](#).

"Science is based not on the prestige of the authors, nor just refined methodology, but on integrity and rigor," says Dr. Luz. He reckons that the peer-review process is essential and adheres to the precepts and was developed with ethical conduct, to avoid the common pitfalls. Therefore, the review must serve as an evaluative judging process, not of authors, but to provide guidance and important adjustments to the study, strengthening the scientific community, and preventing false claims.

Dr. Luz indicates that while reviewing papers, reviewers should keep in mind that every study and methodology has its own weaknesses. Therefore, the evaluation of the study must be focused on adherence to regulations, protocols, and ethical standards. With his experience in statistics, he would focus a lot on whether the analyses were conducted following the appropriate procedures, the tests and models used. Also, it is necessary to have a critical and impartial, as most as possible, view of the results. Conclusions will be free from bias and conflicts of interest on the part of the authors, not inducing certain inappropriate conclusions. Often, reviewers do not have this knowledge of statistics.

"Research, science, is a collective construction carried out based on supportive cooperation among different researchers. One of the reasons a reviewer is precisely the fact that I have already been benefited, not only to improve my articles, but helping me to think more professionally. Therefore, I believe that I can contribute my experience in certain fields and help others to also become professionals," says Dr. Luz.

March, 2024

Benjamin A Teply



Benjamin A. Teply, M.D., is an Associate Professor of Medicine in the Division of Oncology/Hematology at the University of Nebraska Medical Center and a staff physician at Veterans Affairs Nebraska-Western Iowa Veterans Health Care System. He is a medical oncologist who specializes in genitourinary oncology with a research focus in clinical and translational research in prostate cancer. Specific areas of research include clinical trials, novel hormonal manipulation in advanced prostate cancer (e.g., bipolar androgen therapy), non-hormonal therapy options in hormone sensitive disease (e.g., PARP inhibitors), novel biomarkers of therapy resistance (e.g., Neuropilin2) and the optimal use of approved therapies.

From Dr. Teply's point of view, peer review by content experts is the best way to referee science. The process relies on reviewers so that we can trust our body of literature that is informing science and patient care. Although the process can be difficult at times, it ultimately improves the end product of the final published paper.

In addition, Dr. Teply believes that a reviewer needs to first understand the potential importance and promise of a paper and ask questions involving the impact of the work among the other related literature. Being a content expert is critical to this process in order to critique the background/introduction of a paper. He is selective in his reviews in order to make sure he can truly expertly referee the topic. When he does see that the paper is a fit, he tries to make every effort to review the paper.

"The peer-review process of reviewing is almost entirely done behind the scenes by volunteers who are taking time out of their own busy schedules. I have found that participating in this process as a reviewer has its own rewards, however. I always learn something new after reviewing a paper or think about a topic in a different way. By being a reviewer, I have become a better scientist—better at experimental design, anticipating weakness and improving my own work before submission," says Dr. Teply.

11. Interviews with Outstanding Authors (2024)

In 2024, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers. Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields.

William D. Figg



Dr. Figg received a BS in Pharmacy from Samford University and a doctoral pharmacy degree from Auburn University. He completed a clinical internship at the University of Alabama at Birmingham Hospital and a fellowship in Drug Development at the University of North Carolina at Chapel Hill. He also received an MBA from a combined Columbia University and London Business School program. He holds honorary degrees from Georgetown College and the Philadelphia College of Osteopathic Medicine. Dr. Figg joined the National Cancer Institute, the National Institutes of Health, in 1992. He is Chief of the GU Malignancy Branch and Director of the Clinical Pharmacology Program. He has over 875 peer-reviewed publications. He is an adjunct professor of Medicine at Columbia University in New York and adjunct professor of surgery at the Uniformed Services University in Bethesda, Maryland. His research is focused on drug development of novel anticancer agents and prostate cancer. Connect with Dr. Figg on Twitter/X @Will

The way Dr. Figg sees it, it is hard to differentiate between him, an article that changes one's view of biology, a medical journal, and a good academic paper. Those are the seminal papers w

"Joe Friday on the TV show Dragnet would say, 'Just the

Remove the superlatives and be as concise and direct as possible. However, it needs to be detailed for clinical papers to use in their practice," says Dr. Figg.

Grace K. Dy



Dr. Grace K. Dy is a Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. She has served as principal investigator for numerous early phase I clinical trials testing novel therapeutics for advanced solid tumors, including phase II/III trials for advanced-stage thoracic malignancies. She earned her B.S. and M.D. degrees from the University of Santo Tomas in the Philippines, graduating summa cum laude for both degrees. She subsequently completed her internal medicine residency and hematology-oncology fellowship training at Mayo Clinic (Rochester, MN), where she was a recipient of the Oncology Outstanding Achievement Award and the William H.J. Summerskill Award. She is an active member of the International Association for the Study of Lung Cancer (IASLC), the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).

Speaking of the key skill sets of an author, Dr. Dy believes one must be able to distill the essence of concepts into clear and concise statements, yet also be able to shed insight into the nuances in the interpretation of information. Practice is the key. She adds that one must also be aware of the multiple sources of cognitive biases in order to avoid biases.

"With so much information freely available these days, unfortunately, misinformation and disinformation are rampant. My primary motivation to continue academic writing is to contribute our part as members of the scientific community in clarifying concepts and correct any misinterpretation of information," says Dr. Dy.

12. Interviews with Editorial Board Members (2024)

TCR features a distinguished editorial board, the members of which continue to instill the power of their expertise for the journal's development. Hereby, we are glad to spotlight some of them in the form of interviews, in which they will share their unique career experiences and perspectives.

Expert introduction

Prof. Piotr Rutkowski (Figure 1) is the Professor of Surgical Oncology at the Maria Skłodowska-Curie Institute of Oncology in Warsaw, Poland. He is also the current Head of the Department of Soft Tissue/Bone Tumors of Institute for National Oncological Strategy and Clinical Trials at the Maria Skłodowska-Curie Institute. He participated in several investigator-driven trials in melanoma and sarcoma. He is a member of the Editorial Board of *Annals of Surgical Oncology* and *European Journal of Cancer*.

Prof. Rutkowski is an active member of the EORTC Melanoma Group; EORTC Soft Tissue Sarcoma Treatment Subcommittee and the Membership Committee of the EORTC Board. He is also the President of Polish Oncological Society, Board member of Polish Society Surgical Oncology Society, member of International Affair Committee of ASCO, Global Cancer Researcher or co-authored over 500 scientific papers in Polish and international journals (with a highly rewarded Highly Cited Researcher in Clinical Medicine 2021, 2022 and 2023), and is also involved in sarcoma and melanoma. He is working very closely with national patient advocacy groups, the Sarcoma Group and is Chairman of the Melanoma Academy in Poland. Member of the Ministry of Health, Poland for National Oncological Strategy.



Figure 1 Prof. Piotr Rutkowski

Expert introduction

Prof. Tung-Sung Tseng (Figure 1) is an Associate Professor in Behavioral and Community Health Sciences at the School of Public Health, Louisiana State University Health Sciences Center in New Orleans. Prof. Tseng is a Certified Health Education Specialist (CHES)/Master Certified Health Education Specialist (MCHES) and has chaired the Ethics Committee of the Society for Public Health Education (SOPHE).

Prof. Tseng's research has focused on tobacco, cancer, and obesity-related health disparities. His research interests include tobacco control, childhood obesity, risk behavioral patterns, community-based participatory research (CBPR), health promotion interventions and evaluations, health disparities, and cancer prevention among ethnic minorities and underserved populations. As P.I. or co-investigator on several university- and NIH-funded grants, he has been developing effective intervention approaches and collaborated with researchers to identify mediation and interaction effects between a genotype and a social or behavioral risk factor. He has more than 100 peer-reviewed publications and 150 professional conference presentations.

Dr. Tseng has substantial experience in professional leadership and community service activities. He chaired the Ethics Committee of the Society for Public Health Education (SOPHE) and the Genomic Forum of the American Public Health Association (APHA) and was a co-convenor for International Comparisons of Healthy Aging Interest Group, The Gerontological Society of America (GSA). Dr. Tseng also serves as editor, associate editor, reviewer, or member of the review board for thirty more professional journals. He has been recognized with several awards and recognitions, including the Health Education Technology Innovation Award (2024) from the Society for Public Health Education (SOPHE).



Figure 1 Dr. Tung-Sung Tseng

13. Interviews with Guest Editors (2024)

Over the years, a number of TCR guest editors have made valuable contributions to the journal. Hereby, we would like to highlight some of our guest editors, who graciously share their experience in scientific careers and provide insightful perspectives on the special series.

Editor's note

Translational Cancer Research (TCR) has published a number of special series in recent years, receiving overwhelming responses from academic readers around the world. Our success cannot be achieved without the contribution of our distinguished guest editors. This year TCR launched a new column, "Interviews with Guest Editors", to better present our guest editors and to further promote the special series. We also hope to express our heartfelt gratitude for their tremendous effort and to further uncover the stories behind the special series.

The special series "Clinic and Therapeutic Potential of Non-coding RNAs in Cancer"(1) led by Dr. Alfons Navarro (*Figure 1*), Dr. Joan Josep Castellano and Dr. Marina Díaz-Beyá has attracted many readers since its publication. This special series aimed to explore today's knowledge about the potential role of ncRNAs in the clinic, especially in the liquid biopsy field, and intended for the next moment, we are honored to have an interview with Dr. Navarro to share his



Figure 1 Dr. Alfons Navarro

Editor's note

Translational Cancer Research (TCR) has published a number of special series in recent years, receiving overwhelming responses from academic readers around the world. Our success cannot be achieved without the contribution of our distinguished guest editors. This year TCR launched a new column, "Interviews with Guest Editors", to better present our guest editors and to further promote the special series. We also hope to express our heartfelt gratitude for their tremendous effort and to further uncover the stories behind the special series.

This special series "Recent Developments in Benign Tracheal Stenosis" (1) is edited by Dr. Paulo Francisco Guerreiro Cardoso (*Figure 1*), Dr. Benoit Jacques Bibas, and Dr. Konrad Hoetzenecker has attracted many readers since its publication. This special series aims to provide an update on the recent developments in benign tracheal stenosis. Conditions such as stenosis and tracheostomies not only inflict profound suffering on those afflicted but also impose a significant burden on the healthcare system, characterized by high rates of morbidity and mortality, alongside substantial economic costs. At this moment, we are honored to have an interview with Prof. Cardoso to share his scientific career experience and insights on this special series.



Figure 1 Prof. Paulo Francisco Guerreiro Cardoso

14. Introduction of the Publisher AME

Our Publisher—

AME Publishing Company

www.amegroups.com

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world

- **60+** peer-reviewed journals
 - **34** indexed by Web of Science(SCIE/ESCI)
 - **21** indexed in PubMed/PMC/MEDLINE

- **200+** Medical Books
- **80+** Medical Books in English
- **120+** Medical Books in Chinese
- **150+** Electronic Editions

Thank you for all your support!